<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tobramycin and dexamethasone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet"/></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tobramycin and dexamethasone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tobramycin and dexamethasone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11099" href="/d/html/11099.html" rel="external">see "Tobramycin and dexamethasone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F228654"><span class="drugH1">Brand Names: US</span>
<ul>
<li>TobraDex;</li>
<li>TobraDex ST</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914266"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Tobradex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F228671"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic/Corticosteroid, Ophthalmic</li></ul></div>
<div class="block doa drugH1Div" id="F228658"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8246e07-e961-4546-9b70-f8874d198938">Ocular inflammatory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular inflammatory conditions: Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ointment:</b> Apply ~<sup>1</sup>/<sub>2</sub>-inch ribbon in the conjunctival sac of the affected eye(s) up to 3 to 4 times daily</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b></p>
<p style="text-indent:-2em;margin-left:6em;">TobraDex: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; may be increased to 1 to 2 drops every 2 hours for the first 24 to 48 hours, then reduce to less frequent intervals as signs and symptoms improve</p>
<p style="text-indent:-2em;margin-left:6em;">TobraDex ST: Instill 1 drop into the conjunctival sac of the affected eye(s) every 4 to 6 hours; may be increased to 1 drop every 2 hours for the first 24 to 48 hours, then reduce to less frequent intervals as signs and symptoms improve</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5d6908b-d92c-483f-9021-2db65a1a0811">Otitis externa, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis externa, acute (off-label use) (off-label route):</b>
<b>Otic: Suspension:</b> Instill 4 drops into affected ear canal(s) 3 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goguen.1','lexi-content-ref-35848194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goguen.1','lexi-content-ref-35848194'])">Ref</a></span>). Treatment duration is usually 7 days and may be extended an additional 7 days if symptoms are improving but not yet resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24491310']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24491310'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991151"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50988504"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F228659"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F228666"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8246e07-e961-4546-9b70-f8874d198938">Ocular inflammatory conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular inflammatory conditions:</b> Children ≥2 years and Adolescents: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192781"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51192782"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F228635"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (&lt;4%), conjunctival erythema (&lt;4%), eyelid pruritus (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F228646"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to tobramycin, dexamethasone, or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial infection of the eye; fungal diseases of ocular structure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: Additional contraindications (not in US labeling):</i> Patients with known or suspected hypersensitivity to other aminoglycosides; after uncomplicated removal of a corneal foreign body; untreated parasitic or untreated acute purulent infections of the eye.</p></div>
<div class="block war drugH1Div" id="F228632"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Sensitivity varying from local to generalized effects (eg, erythema, pruritus, urticaria, skin rash, anaphylaxis, anaphylactoid reaction, bullous reaction) to topically applied aminoglycosides may occur; discontinue if sensitivity reaction occurs. Cross-sensitivity to other aminoglycoside antibiotics may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary ocular infections (including fungal infections). Acute purulent or parasitic ocular infections may be masked or exacerbated with use. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Prolonged use may result in glaucoma, injury to the optic nerve, visual defects in acuity and field of vision, and formation of posterior subcapsular cataracts. Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use after cataract surgery may delay healing and increase the incidence of bleb formation. Intraocular pressure should be monitored if this product is used &gt;10 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular herpes simplex: Use with extreme caution in patients with a history of ocular herpes simplex; use of corticosteroids may prolong the course and exacerbate severity of infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: May contain benzalkonium chloride (ophthalmic suspension) which may be adsorbed by contact lenses; contact lenses should not be worn during treatment of ophthalmic infections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical ophthalmic use only. A maximum of 8 g of ointment or 20 mL of suspension should be prescribed initially; patients should be evaluated prior to additional refills. Patients should be re-evaluated if symptoms do not improve after 2 days. Monitor intraocular pressure if this product is used &gt;10 days. Initial prescription and renewal of medication should be made by health care provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). Inadvertent contamination of multiple-dose ophthalmic bottle dropper and tips has caused bacterial keratitis.</p></div>
<div class="block foc drugH1Div" id="F228641"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment, Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">TobraDex: Tobramycin 0.3% and dexamethasone 0.1% (3.5 g) [contains chlorobutanol]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">TobraDex: Tobramycin 0.3% and dexamethasone 0.1% (2.5 mL [DSC], 5 mL [DSC], 10 mL [DSC]) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;">TobraDex ST: Tobramycin 0.3% and dexamethasone 0.05% (5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Tobramycin 0.3% and dexamethasone 0.1% (2.5 mL, 5 mL, 10 mL)</p></div>
<div class="block geq drugH1Div" id="F228628"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes: Suspension (0.3%/0.1%)</p></div>
<div class="block fee drugH1Div" id="F228647"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (TobraDex Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3-0.1% (per gram): $93.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (TobraDex ST Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3-0.05% (per mL): $57.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Tobramycin-dexAMETHasone Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3-0.1% (per mL): $18.25 - $29.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56514538"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment, ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Tobradex: Tobramycin 0.3% and dexamethasone 0.1% (3.5 g) [contains chlorobutanol]</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, ophthalmic:</p>
<p style="text-indent:-2em;margin-left:4em;">Tobradex: Tobramycin 0.3% and dexamethasone 0.1% (5 mL) [contains benzalkonium chloride]</p></div>
<div class="block adm drugH1Div" id="F228643"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ophthalmic: </b>Contact lenses should not be worn during therapy. Per the manufacturer, for topical ophthalmic use only; to avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ointment:</b> Apply ointment into pocket between eyeball and lower lid; patient should look downward before closing eye.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b> Shake well before using. Tilt head back, instill suspension in conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Otic (off-label route):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b> Shake well before using. Thoroughly cleanse external auditory canal and dry with a sterile cotton applicator. Lie down with affected ear upward and medication instilled. Maintain this position for 3 to 5 minutes to facilitate penetration of the drops. Repeat, if necessary, for the opposite ear. Alternatively, insert a cotton wick impregnated with tobramycin 0.3%/dexamethasone 1% drops (or a dry wick subsequently saturated with the suspension) into the ear canal. This wick should be kept moist by adding further suspension 3 to 4 times daily. The wick is unnecessary after ear canal edema subsides, typically in 24 to 48 hours. The otic route should not be used when the integrity of the tympanic membrane is in question (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24491310','lexi-content-ref-35848194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24491310','lexi-content-ref-35848194'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613940"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For topical ophthalmic use only; not for injection into the eye. To avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes. Contact lenses should not be worn during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Tilt head back and apply ointment into pocket between eyeball and lower lid (conjunctival sac); patient should look downward before closing eye.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake well before using. Tilt head back, instill suspension in conjunctival sac, and close eye(s).</p></div>
<div class="block use drugH1Div" id="F228642"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Ocular inflammatory conditions:</b> Treatment of steroid-responsive ocular inflammatory conditions (where either a superficial bacterial ocular infection or the risk of a bacterial ocular infection exists) of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe; chronic anterior uveitis; corneal injury from chemical, radiation or thermal burns; penetration of foreign bodies.</p></div>
<div class="block off-label drugH1Div" id="F58295218"><span class="drugH1">Use: Off-Label: Adult</span><p>Otitis externa, acute</p></div>
<div class="block mst drugH1Div" id="F228676"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">TobraDex may be confused with Tobrex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300150"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F228636"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DexAMETHasone (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Corticosteroids (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F228648"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed with topical corticosteroids in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988). See individual agents.</p></div>
<div class="block brc drugH1Div" id="F228649"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if systemic absorption following topical administration results in detectable quantities in human milk. The manufacturer recommends that caution be exercised when administering tobramycin/dexamethasone to breast-feeding women. See individual agents.</p></div>
<div class="block mop drugH1Div" id="F228639"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor intraocular pressure with use &gt;10 days and in patients with glaucoma; signs/symptoms of secondary infection; re-evaluate if signs and symptoms persist beyond 2 days.</p></div>
<div class="block pha drugH1Div" id="F228631"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Tobramycin: Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit resulting in a defective bacterial cell membrane.</p>
<p style="text-indent:-2em;margin-left:2em;">Dexamethasone: Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response.</p></div>
<div class="block phk drugH1Div" id="F228645"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;text-align:justify;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F228650"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bicrinol | Bideon Biotic Plus | Bio eyes plus | Biocort | Fotadex | Gotabiotic f | Klonamicin compuesto | Radina dex | Tobracort | Tobratlas dexa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cinarex D | Decason c | Dextrobac | Infladex TN | T-Dex | Tobidex | Torcin d</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tobradex | Tobramed</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Tobracin d</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Flures d | Poentobral plus | Tobradex | Todexona | Xolof D</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dian shu | Tobradex | Tobramycin and dexamethasone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acudex | Dexavital | Dextopharm | Expomicina d | Mirabet-T | Ophthabracin d | Tobracort | Tobragan d | Tobramicina + dexametasona | Tobramisona | Tobraoftal D | Tobratlas | Trazidex ofteno | Trazil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dexatobrimin | Obicin D | Obrydex | Poentobral plus | Protaba | Tobradex | Tobramisona | Tosobrel dex | Trazidex ofteno | Xolof D</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Poentobral plus | Tobragan d | Tobral D | Tobramisona | Trazidex ofteno | Xolof D</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dexatobrin | Farcobrasone | Optidex t | Selectomycin D | Tobracoid | Tobradex</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lofoto | Oclex | Tobaren</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dexamycin | Lofoto | O biotic | Tobradex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Tobadexa | Tobeson | Tobradex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Tobradex | Todep</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bralifex plus | Isotic tobrizon | Tobroson</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Gb cin d | Nebracin DM | Obra-D | Obrasone | Ocutob-d | Toba-DM | Tobacin D | Tobadex | Tobagram d | Tobaren d | Tobaren-d | Tobazon DM | Tobracid-dm | Tobrafil dm | Tobrop-DM | Tojawa D | Tromadex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Coldetom | Combitimor | Eucombidex | Tobradex | Tobradex oto | Tobramicina e desametasone doc generici | Tobramicina e desametasone eg | Trigon | Vardamir | Visucombidex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lofoto | Optidex t | Tobradex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alemtob d | Ocutob-d | Orbidex t | Tob dex | Tobracid dm</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bitodex | Dicon | Eyedexin | I dexin | I todex | Litetodex | Oclex | Ritodex | Ronotix | Tobacin D | Tobadex | Tobadexa | Tobaren | Tobeson | Tobradex | Tobrich | Tobtwo | Torabindex | Union tobradex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Tobra-d | Tobracort | Tobradex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bropdex | Tobradex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alesiram | Dosebrax | Isenia dex | Obrameth | Obrydex | Poentobral f | Segucor | Son'ssimet | Tobracort | Tobradex | Tobramicina, dexametasona | Trazidex | Trazidex ofteno</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Kinglion tobramycin &amp; dexamethasone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Gotabiotic plus | Tobracort | Tobragan d | Tobramisona</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Nebracin DM | Orbidex t | Sensomed tobramycin/dexamethasone | Tobradex | Tobramycin + Dexamethasone Celsus</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arodex | Bracin-D | Bradex | Bromycin-d | Cindex | Dexatob | Dicon | Eyebradex | Mebradex | Meditob d | Ocutobdex | Ophth-Tobra-D | Optibrex d | Orcydex | Raydex t | Santodex | Tobcoid | Tobec d | Tobidex | Tobowin | Tobra-d | Tobracin d | Tobradex | Tobramet | Tobrason | Typhodex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citol dexa + tobra | Gotabiotic f | Oftalmol td | Tobradex | Tobratlas dexa | Tolbet d | Xolof D</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Optidex T | Tobradex | Tobrason</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dexatobrom</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dexatobropt | Tobradex | Tobrasone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tobracort</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Combidex | Medetrom | Tobradex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tobradex</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Medetrom | Obradex | Tobiflamin | Tobrosodex | Tobrosopt dex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Belpartex | Decor Plus | Gotabiotic plus | Tobraxona</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cofatodex | Dextobram | Poentobral plus | Tobradex | Tobramycin + Dexamethasone | Tobrawell dx | Tomycin d</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Alembic alemtob d | Bratorex dexa | Detoraxin | Govarom | Metodex | Philoclex | Tobradico d | Todexe | Torexvis d | Vatiwed</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ocutob-d | Tobradex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Goguen.1">
<a name="Goguen.1"></a>Goguen LA. External otitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35848194">
<a name="35848194"></a>Rasheed AM, Hilal SA, Abbas AM. Is adding an oral antibiotic with the topical antibiotic steroid useful in treatment of uncomplicated acute otitis externa in immunocompetent patients? <i>J Popul Ther Clin Pharmacol</i>. 2022;29(2):e27-e32. doi:10.47750/jptcp.2022.927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-and-dexamethasone-drug-information/abstract-text/35848194/pubmed" id="35848194" target="_blank">35848194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24491310">
<a name="24491310"></a>Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical practice guideline: acute otitis externa.<i> Otolaryngol Head Neck Surg</i>. 2014;150(1 suppl):S1-S24. doi:10.1177/0194599813517083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-and-dexamethasone-drug-information/abstract-text/24491310/pubmed" id="24491310" target="_blank">24491310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-and-dexamethasone-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23198673">
<a name="23198673"></a>Schaefer P, Baugh RF. Acute otitis externa: an update. <i>Am Fam Physician</i>. 2012;86(11):1055-1061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tobramycin-and-dexamethasone-drug-information/abstract-text/23198673/pubmed" id="23198673" target="_blank">23198673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobradex.1">
<a name="Tobradex.1"></a>Tobradex Ointment and Suspension (tobramycin and dexamethasone) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobradex.2">
<a name="Tobradex.2"></a>TobraDex ST (tobramycin/dexamethasone) [prescribing information]. Fort Worth, TX: Eyevance Pharmaceuticals LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobradex.3">
<a name="Tobradex.3"></a>TobraDex Suspension (tobramycin/dexamethasone) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobradex.4">
<a name="Tobradex.4"></a>TobraDex (tobramycin/dexamethasone) ointment [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tobradex.5">
<a name="Tobradex.5"></a>TobraDex (tobramycin/dexamethasone) suspension [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10001 Version 173.0</div></div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
